mefazide, 150 mg + 100 mg, comprimé / tablet, b/10 x100 sous blisters
maneesh pharmaceuticals pvt ltd - rifampicine+ isoniazide - comprimé / tablet - 150 mg + 100 mg
rifadine, 300 mg, gélule/capsule, b/30
marion merrell s.a. - rifampicine - gélule/capsule - 300 mg
rifadine, 2 g, suspension orale/oral suspension, fl/120 ml
marion merrell s.a. - rifampicine - suspension orale/oral suspension - 2 g
rifoderm, 0,250 g/1 g, pommade/ointment, t/5 g
pfizer holding france - rifampicine sv/prednisolone - pommade/ointment - 0,250 g/1 g
rifoderm, 0,250 g/1 g, pommade/ointment, t/15g
pfizer holding france - rifampicine sv/prednisolone - pommade/ointment - 0,250 g/1 g
rimactan, 300 mg, gélule/capsule, b/30
novartis pharma s.a. - rifampicine - gélule/capsule - 300 mg
rimactan 2 pour cent, sirop
sandoz - rifampicine - sirop - 2 g - composition pour 100 ml > rifampicine : 2 g
rimactan iv 300 mg, poudre et solvant pour solution pour perfusion
sandoz - rifampicine sodique - poudre - 300 mg - composition pour un flacon > rifampicine sodique : 300 mg solvant composition > pas de substance active. :
tivicay
viiv healthcare bv - dolutégravir - infections au vih - antiviraux à usage systémique - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - infections au vih - antiviraux à usage systémique - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.